Immunostimulation of dendritic cells by cationic liposomes

References

• Cox JC, Coulter AR. Adjuvants – a classification and review of their modes of action. Vaccine 1997; 15: 248–256
   PubMed Web of Science ®Google Scholar
• Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17: 1075–1081
   PubMed Web of Science ®Google Scholar
• Brunel F, Darbouret A, Ronco J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 1999; 17: 2192–2203
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72: 1608–1617
   PubMed Web of Science ®Google Scholar
• Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (Lipodine)-mediated DNA vaccination by the oral route. J Liposome Res 2002; 12: 185–197
   PubMed Web of Science ®Google Scholar
• Felgner PL, Kumar R, Basava C, Border RC, Hwang-Felgner JY. 1993. Cationic lipids for intracellular delivery of biologically active molecules. US Patent 5,459,127.
   Google Scholar
• Alving CR, Koulchin V, Glenn GM, Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 1995; 145: 5–31
   PubMed Web of Science ®Google Scholar
• Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD, Jr, Huang L. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 2003; 7: 640–648
   PubMed Web of Science ®Google Scholar
• Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997; 4: 891–900
   PubMed Web of Science ®Google Scholar
• Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999; 6: 1867–1875
   PubMed Web of Science ®Google Scholar
• Whitmore MM, Li S, Falo L, Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001; 50: 503–514
   PubMed Web of Science ®Google Scholar
• Li S, Wu SP, Whitmore M, Loeffert EJ, Wang L, Watkins SC, Pitt BR, Huang L. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 1999; 276: L796–804
   PubMed Web of Science ®Google Scholar
• Okada N, Saito T, Mori K, Masunaga Y, Fujii Y, Fujita J, Fujimoto K, Nakanishi T, Tanaka K, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochim Biophys Acta 2001; 1527: 97–101
   PubMed Web of Science ®Google Scholar
• Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003; 23: 243–247
   PubMedGoogle Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740–745
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085–2088
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2005; 2: 22–28
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526–1529
   PubMed Web of Science ®Google Scholar
• Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861–1872
   PubMed Web of Science ®Google Scholar
• Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278: 1612–1615
   PubMed Web of Science ®Google Scholar
• Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001; 166: 5688–5694
   PubMed Web of Science ®Google Scholar
• Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001; 167: 5887–5894
   PubMed Web of Science ®Google Scholar
• Baker PJ, Hraba T, Taylor CE, Myers KR, Takayama K, Qureshi N, Stuetz P, Kusumoto S, Hasegawa A. Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity. Infect Immun 1992; 60: 2694–2701
   PubMed Web of Science ®Google Scholar
• Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, Glauser MP, Baumgartner JD. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992; 148: 3505–3512
   PubMedGoogle Scholar
• Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160: 3081–3085
   PubMed Web of Science ®Google Scholar